Safety and efficacy study of Umbilical cord mesenchymal stem cells transpIantation for treatment of Parkinson's disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-12002937

Enrollment

Unknown

Registered

2012-12-10

Start date

2012-11-03

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Lumbar puncture stem cells therapy:Infusion of Umbilical cord mesenchymal stem cells

Vein stem cells therapy:Infusion of Umbilical cord mesenchymal stem cells

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: The subiects were in accordance with diagnostic criteria of dyskinesia and Parkinson's disease, formuIated by Chinese Medjcal AssociationNeurology Branch in 2006, Exclude other degenerative diseases of the nervous system and no other major diseases.

Exclusion criteria

Exclusion criteria: 1. Highly allergies or a history of severe allergic; 2. Malignant tumor; 3. Systemic infection or severe localized infection; 4. Merger hair cardiopulmonary liver and kidney dysfunction of vital organs; 5. Coagulation disorders,such as hemophilia; 6. Serological tests positiveSuch as AIDS, hepatitis B, and syphilis.

Design outcomes

Primary

Measure	Time frame
Nerve function assessment by UPDRS;Safety indexes: blood, uring, stool routing test, liver and kidney function test, blood glucosis, blood lipids, X-ray chest examination, ECG;	—

Countries

China

Contacts

Public ContactQingsong Wang

wangqs65@yahoo.com+86 18909696277

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026